Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Stroke; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CANVAS-R; CANVAS-Renal
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 30 Nov 2023 Results of pooled analysis assessing effects of canagliflozin on clinical outcomes and intermediate markers of subgroups according to population-specific BMI , from the NCT01032629, NCT01989754 and NCT02065791 studies published in the Diabetes, Obesity and Metabolism.
    • 21 Jul 2023 Results of a pooled post-hoc analysis from two clinical studies: CANVAS Program (NCT01032629 and NCT01989754) CREDENCE (NCT02065791) assessing whether canagliflozin affects risk of non-genital skin and soft tissue infections published in the Diabetes, Obesity and Metabolism
    • 07 May 2023 Results of secondary post-hoc analysis from CANVAS (NCT01032629) and CANVAS-R (NCT01989754) studies assessing (n=10131) the efficacy of canagliflozin in patients with diabetes mellitus, published in the Journal of Clinical Endocrinology and Metabolism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top